Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States

American Journal of Health-System Pharmacy

Volumn 56, Issue 14, 1999, Pages 1427-1432

  Connor, Thomas H ^a   Anderson, Roger W ^b   Sessink, Paul J M ^c   Broadfield, Larry ^d   Power, Luci A ^e  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Exposure Control   (Netherlands)

^d JURAVINSKI CANCER CENTRE   (Canada)

^e Power Enterprises   (United States)

Author keywords

Antineoplastic agents; Compounding; Contamination; Cyclophosphamide; Drug administration; Fluorouracil; Ifosfamide; Pharmacy, institutional, hospital; Toxicity, environmental

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; IFOSFAMIDE; SODIUM HYDROXIDE;

ARTICLE; CANADA; CANCER CENTER; CONTAMINATION; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET RADIATION; UNITED STATES;

EID: 0033565504     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.14.1427     Document Type: Article

References (53)

1. Falck K, Gröhn P, Sorsa M et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet. 1979; 1:1250-1. Letter.
2. U.S. Department of Labor. Guidelines for cytotoxic (antineoplastic) drugs. Washington, DC: U.S. Occupational Health and Safety Administration, Office of Occupational Medicine, 1986; publication no. 8-1.1.
3. OSHA Instruction TED 1.15. Directorate of technical support. Controlling occupational exposure to hazardous drugs. Washington, DC: U.S. Occupational Health and Safety Administration; 1995.
4. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. Am J Hosp Pharm. 1985; 42:131-7.
5. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033-49.
6. Oncology Nursing Society. Standards for cancer nursing practice. Pittsburgh: Oncology Nursing; 1982.
7. Powell L, ed. Cancer chemotherapy guidelines and recommendations for practice. Pittsburgh: Oncology Nursing; 1996.
8. Clinical Oncology Society of Australia. Guidelines for safe handling of antineoplastic agents. Med J Aust. 1983; 1:426-8.
9. AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985; 253:1590-2.
10. Recommendations for handling cytotoxic agents. Providence, RI: National Study Commission on Cytotoxic Exposure; 1987 Sep.
11. Guidelines for the handling and disposal of hazardous pharmaceuticals (including cytotoxic drugs). Ottawa, Ontario, Canada: Canadian Society of Hospital Pharmacists; 1993.
12. Davis J, Jackson J, Kirsa, S et al. SHPA standards of practice for the safe handling of cytotoxic drugs in pharmacy departments. Melbourne, Australia: Society of Hospital Pharmacists of Australia; 1997:8-1-8-10.
13. Council directive of 28 June 1990 on the protection of workers from the risks related to exposure to carcinogens at work (90/394/EEC). Official Journal of the European Communities. No. L 196/1-7. 1990 Jul 26.
14. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health-Syst Pharm. 1996; 53:2713-23.
15. Sorsa M, Anderson D. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat Res. 1996; 355:253-61.
16. Bos RP, Sessink PJM. Biomonitoring of occupational exposure to cytostatic anticancer drugs. Rev Environ Health. 1997; 12:43-58.
17. Valanis B, Shortridge L. Self protective practices of nurses handling antineoplastic drugs. Oncol Nurs Forum. 1987; 14: 23-7.
18. Valanis B, McNeil V, Driscoll K. Staff members' compliance with their facility's antineoplastic drug handling policy. Oncol Nurs Forum. 1991; 18:571-6.
19. Mayer DK. Hazards of chemotherapy: implementing safe handling practices. Cancer. 1992; 70(suppl):988-92.
20. Valanis B, Vollmer WM, Labuhn K et al. Antineoplastic drug handling protection after OSHA guidelines: comparison by profession, handling activity and work site. J Occup Med. 1992; 34:149-55.
21. Mahon SM, Casperson DS, Yackzan S et al. Safe handling practices of cytotoxic drugs: the results of a chapter survey. Oncol Nurs Forum. 1994; 21:1157-65.
22. Nieweg RMB, de Boer M, Dubbleman RC et al. Safe handling of antineoplastic drugs. Cancer Nurs. 1994; 17:501-11.
23. Christensen CJ, Lemasters GK, Wakeman MA. Work practices and policies of hospital pharmacists preparing antineoplastic agents. J Occup Med. 1990; 32:508-12.
24. Sessink PJM, Timmersmans JL, Anzion RB et al. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. J Occup Med. 1994; 36:79-83.
25. Sessink PJM, Friemèl NSS, Anzion RBM et al. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health. 1994; 65:401-3.
26. Sessink PJM, Anzion RB, Van den Broek PHH et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992; 14:16-22.
27. Sessink PJM, Boer KA, Scheefhals APH et al. Occupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992; 64:105-12.
28. Sessink PJM, Van de Kerkhof MCA, Anzion RB et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health. 1994; 49:165-9.
29. Pethran A, Hauff K, Hessel H et al. Biological, cytogenetic, and ambient monitoring of exposure to antineoplastic drugs. J Oncol Pharm Pract. 1998; 4:57. Abstract.
30. Sessink PJM, Wittenhorst BCJ, Anzion RBM et al. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health. 1997; 52:240-4.
31. McDevitt JJ, Lees PSJ, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993; 35:57-60.
32. Evelo CTA, Bos RP, Peters JGP et al. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health. 1986; 58:151-5.
33. Ensslin AS, Pethran A, Schierl R et al. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health. 1994; 65:339-42.
34. Ensslin AS, Stoll Y, Pethran A et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med. 1994; 51:229-33.
35. Sessink PJM, Cerná M, Rössner P et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res. 1994; 309:193-9.
36. Ensslin AS, Huber R, Pethran A et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health. 1997; 70:205-8.
37. Bos RP, Weissenberger BFJ, Anzion RBM. α-fluoro-β-alanine in urine of workers occupationally exposed to 5-fluorouracil in a 5-fluorouracil-producing factory. Biomarkers. 1998; 3:81-7.
38. Sessink PJM, Scholtes MM, Anzion RBM et al. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr. 1993; 616:333-7.
39. Nguyen TV, Theiss JC, Matney TS et al. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res. 1982; 42:4792-6.
40. Anderson RW, Puckett WH, Dana WJ et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982; 39:1881-7.
41. Kolmodin-Hedman B, Hartvig P, Sorsa M et al. Occupational handling of cytostatic drugs. Arch Toxicol. 1983; 54:25-33.
42. Lovejoy N, Powers L, Flessel P et al. Mutagenicity in urine of hospital workers who prepare and administer chemotherapy agents. Environ Mutat. 1985; 7(suppl 3):5. Abstract.
43. Connor TH, Theiss JC, Anderson RW et al. Re-evaluation of urine mutagenicity of pharmacy personnel exposed to anti-neoplastic agents. Am J Hosp Pharm. 1986; 43:1236-9.
44. Fuchs J, Hengstler JG, Jung D et al. DNA damage in nurses handling antineoplastic agents. Mutat Res. 1995; 342:17-23.
45. Sessink PJM, Kroese ED, van Kranen HJ et al. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1993; 67:317-23.
46. International Agency for Research on Cancer Home Page [resource on World Wide Web]. URL: http://www.iarc.fr. Available from Internet. Accessed 1998 Apr 16.
47. Pui C, Behm F, Raimondi S. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989; 321:136-42.
48. Winick NJ, McKenna RW, Shuster JJ et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993; 11:209-17.
49. Hansen J, Olsen JH. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health. 1994; 20:22-6.
50. Valanis BG, Vollmer WM, Labuhn KT et al. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993; 50:455-62.
51. Valanis BG, Vollmer WM, Labuhn KT et al. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs. 1993; 16:288-95.
52. Valanis B, Vollmer W, Labuhn K et al. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997; 39:574-80.
53. Opiolka S, Mölter, Goldschmidt R et al. Umgang mit Zytostatika. Krankenhaus Technik, 1998; Mar:56-8.